EyePoint Pharmaceuticals, Inc., a specialty biopharmaceutical company, develops and commercializes ophthalmic products for the treatment of eye diseases in the United States and Europe. It provides ILUVIEN for the treatment of diabetic macular edema; YUTIQ, a non-erodible fluocinolone acetonide insert for the treatment of non-infectious posterior uveitis (NIPU) that is in the Phase III clinical trials; and Retisert (fluocinolone acetonide intravitreal implant), a sustained-release implant for the treatment of posterior segment uveitis. The company also offers DEXYCU (dexamethasone intraocular suspension), an intraocular product for the treatment of postoperative ocular inflammation; and Vitrasert (ganciclovir), a sustained release implant for the treatment of cytomegalovirus retinitis. In addition, it develops YUTIQ shorter-acting uveitis for the treatment of NIPU; and Durasert tyrosine kinase inhibitor for the treatment of wet age-related macular degeneration. Further, the company's development program focuses on developing sustained release products using its Durasert and Verisome technology platforms to deliver drugs to treat chronic diseases. It has strategic collaborations with Alimera Sciences, Inc., Bausch & Lomb, OncoSil Medical UK Limited, and Ocumension Therapeutics. The company was formerly known as pSivida Corp. and changed its name to EyePoint Pharmaceuticals, Inc. in March 2018. EyePoint Pharmaceuticals, Inc. was founded in 1987 and is headquartered in Watertown, Massachusetts.
Industry, Sector and Symbol
Industry Analytical instruments
Sub-IndustryN/A
SectorMedical
Phone617-926-5000
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$2.96 million
Profitability
Miscellaneous
Employees55
Next Earnings Date9/11/2019 (Estimated)
OptionableOptionable
Eyepoint Pharmaceuticals (NASDAQ:EYPT) Frequently Asked Questions
What is Eyepoint Pharmaceuticals' stock symbol?
Eyepoint Pharmaceuticals trades on the NASDAQ under the ticker symbol "EYPT."
How were Eyepoint Pharmaceuticals' earnings last quarter?
Eyepoint Pharmaceuticals Inc (NASDAQ:EYPT) issued its quarterly earnings results on Wednesday, May, 8th. The company reported ($0.16) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.13) by $0.03. The business had revenue of $2.01 million for the quarter, compared to analysts' expectations of $3.70 million. Eyepoint Pharmaceuticals had a negative net margin of 1,739.81% and a negative return on equity of 195.83%. View Eyepoint Pharmaceuticals' Earnings History.
When is Eyepoint Pharmaceuticals' next earnings date?
What price target have analysts set for EYPT?
2 Wall Street analysts have issued 12-month target prices for Eyepoint Pharmaceuticals' shares. Their forecasts range from $4.50 to $6.00. On average, they anticipate Eyepoint Pharmaceuticals' stock price to reach $5.25 in the next year. This suggests a possible upside of 194.9% from the stock's current price. View Analyst Price Targets for Eyepoint Pharmaceuticals.
What is the consensus analysts' recommendation for Eyepoint Pharmaceuticals?
2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Eyepoint Pharmaceuticals in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Eyepoint Pharmaceuticals.
What are Wall Street analysts saying about Eyepoint Pharmaceuticals stock?
Here are some recent quotes from research analysts about Eyepoint Pharmaceuticals stock:
- 1. According to Zacks Investment Research, "EyePoint Pharmaceuticals Inc. operates as a biopharmaceutical company. It engaged in the development of drug devices to treat debilitating diseases of the eye disorders and other chronic conditions. The company's product candidate consists of DEXYCU(TM). EyePoint Pharmaceuticals Inc., formerly known as pSivida Corp., is headquartered in Watertown, MA. " (5/14/2019)
- 2. HC Wainwright analysts commented, "We note that this is the first quarter that the company reports product sales after the commercial launch of YUTIQ and DEXYCU. the company launched YUTIQ (fluocinolone acetonide intravitreal implant) 0.18 mg for up to three years of continuous treatment of chronic, non-infectious posterior segment uveitis. YUTIQ sales in 1Q19 were $543K based on roughly 77 units delivered to distributors. the company launched DEXYCU (dexamethasone intraocular suspension) 9% as a single dose intraocular steroid product for the treatment of post-operative ocular inflammation. DEXYCU sales in 1Q19 were $684K based on roughly 1352 units delivered to distributors. In our view, these market uptake data are impressive given the short period of time the products are available during 1Q19." (5/9/2019)
Has Eyepoint Pharmaceuticals been receiving favorable news coverage?
News articles about EYPT stock have trended somewhat positive on Wednesday, InfoTrie Sentiment reports. The research firm rates the sentiment of news coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. Eyepoint Pharmaceuticals earned a media sentiment score of 1.5 on InfoTrie's scale. They also assigned press coverage about the company a news buzz of 10.0 out of 10, meaning that recent news coverage is extremely likely to have an impact on the stock's share price in the near term.
Are investors shorting Eyepoint Pharmaceuticals?
Eyepoint Pharmaceuticals saw a decrease in short interest during the month of April. As of April 15th, there was short interest totalling 2,720,787 shares, a decrease of 48.4% from the March 29th total of 5,276,290 shares. Based on an average daily volume of 497,509 shares, the days-to-cover ratio is currently 5.5 days. Currently, 5.7% of the shares of the company are sold short. View Eyepoint Pharmaceuticals' Current Options Chain.
Who are some of Eyepoint Pharmaceuticals' key competitors?
What other stocks do shareholders of Eyepoint Pharmaceuticals own?
Who are Eyepoint Pharmaceuticals' key executives?
Eyepoint Pharmaceuticals' management team includes the folowing people:
- Ms. Nancy S. Lurker, Pres, CEO & Director (Age 62)
- Mr. Leonard S. Ross, VP of Fin. & Chief Accounting Officer (Age 69)
- Dr. Dario A. Paggiarino, VP & Chief Medical Officer (Age 62)
- Mr. David J. Price, Chief Financial Officer (Age 56)
- Mr. Marty Nazzaro, Sr. VP of Operations
Who are Eyepoint Pharmaceuticals' major shareholders?
Eyepoint Pharmaceuticals' stock is owned by many different of retail and institutional investors. Top institutional investors include HighTower Advisors LLC (4.98%), BlackRock Inc. (1.10%), Essex Investment Management Co. LLC (0.52%), Renaissance Technologies LLC (0.36%), Morgan Stanley (0.30%) and Regal Investment Advisors LLC (0.18%). Company insiders that own Eyepoint Pharmaceuticals stock include Douglas Evan Godshall, Ew Healthcare Partners, LP, Jay S Duker, John B Landis and Nancy Lurker. View Institutional Ownership Trends for Eyepoint Pharmaceuticals.
Which institutional investors are selling Eyepoint Pharmaceuticals stock?
Which institutional investors are buying Eyepoint Pharmaceuticals stock?
EYPT stock was bought by a variety of institutional investors in the last quarter, including Regal Investment Advisors LLC, Laurion Capital Management LP, Tibra Equities Europe Ltd, Kore Private Wealth LLC, ExodusPoint Capital Management LP, Citigroup Inc., Jefferies Group LLC and Morgan Stanley. Company insiders that have bought Eyepoint Pharmaceuticals stock in the last two years include Douglas Evan Godshall, Ew Healthcare Partners, LP, Jay S Duker, John B Landis and Nancy Lurker. View Insider Buying and Selling for Eyepoint Pharmaceuticals.
How do I buy shares of Eyepoint Pharmaceuticals?
Shares of EYPT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Eyepoint Pharmaceuticals' stock price today?
One share of EYPT stock can currently be purchased for approximately $1.78.
How big of a company is Eyepoint Pharmaceuticals?
Eyepoint Pharmaceuticals has a market capitalization of $188.87 million and generates $2.96 million in revenue each year. The company earns $-53,170,000.00 in net income (profit) each year or ($0.58) on an earnings per share basis. Eyepoint Pharmaceuticals employs 55 workers across the globe.
What is Eyepoint Pharmaceuticals' official website?
How can I contact Eyepoint Pharmaceuticals?
Eyepoint Pharmaceuticals' mailing address is 480 PLEASANT STREET, WATERTOWN MA, 02472. The company can be reached via phone at 617-926-5000 or via email at [email protected]
MarketBeat Community Rating for Eyepoint Pharmaceuticals (NASDAQ EYPT)
MarketBeat's community ratings are surveys of what our community members think about Eyepoint Pharmaceuticals and other stocks. Vote "Outperform" if you believe EYPT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe EYPT will underperform the S&P 500 over the long term. You may vote once every thirty days.
